Seeking Alpha

Bristol-Myers Squibb (BMY) is set to complete its $7B acquisition of Amylin Pharmaceuticals...

Bristol-Myers Squibb (BMY) is set to complete its $7B acquisition of Amylin Pharmaceuticals (AMLN) after reciving tenders for 85.55% of the latter's shares. Under the deal, AztraZenica (AZN) will now pay $3.4B to Bristol-Myers as part of a collaboration agreement for the development and commercialization of Amylin's products. (PR)
Comments (1)
  • I like low P/E drug stocks with good dividends.
    8 Aug 2012, 06:10 PM Reply Like
DJIA (DIA) S&P 500 (SPY)